Elanco executive granted deferred stock units

Correia de Simas Jose Manuel reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 03/10/2026 - 04:14 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Correia de Simas Jose Manuel reported acquisition or exercise transactions in this Form 4 filing.

Elanco Animal Health officer Correia de Simas Jose Manuel received a grant of 17,637.8425 deferred stock units on Company common stock at a reference value of $23.36 per unit. Following this award, he holds 22,280.4709 deferred stock units. These units will be settled in cash or shares after employment ends or in a designated future year under the Executive Deferral and Stock Match Plan.

Insider Trade Summary

Grant/Award: 17,637.8425 shares

Grant/Award 1 txn

Insider Correia de Simas Jose Manuel

Role SEE REMARKS

Type	Security	Shares	Price	Value
Grant/Award	Deferred Stock Units	17,637.8425	$23.36	$412K

Holdings After Transaction: Deferred Stock Units — 22,280.4709 contracts (Direct)

Holdings Before and After: Deferred Stock Units, 4,642.6284 to 22,280.4709 contracts (Direct)

Footnotes (2)

1. F1. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.
2. F2. Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Elanco (ELAN) report in this Form 4?

Elanco reported that officer Correia de Simas Jose Manuel received 17,637.8425 deferred stock units. These units reference Company common stock at $23.36 per unit and increase his total deferred stock unit holdings to 22,280.4709 under the Executive Deferral and Stock Match Plan.

What are the key terms of the deferred stock units granted at Elanco (ELAN)?

Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. The units were granted at a reference value of $23.36 per unit and settle at a later date under the company’s executive deferral plan.

How many deferred stock units does the Elanco (ELAN) officer hold after this grant?

After the grant, the officer holds a total of 22,280.4709 deferred stock units. This includes the new 17,637.8425-unit award and any existing balance, all governed by Elanco’s Executive Deferral and Stock Match Plan for future settlement in cash or shares.

When will the Elanco (ELAN) deferred stock units be settled?

The deferred stock units will be settled in cash or Elanco common shares after the officer’s termination of employment or during a specified future year. Settlement timing follows the rules of the company’s Executive Deferral and Stock Match Plan elections.

Does this Elanco (ELAN) Form 4 reflect a market purchase or sale of stock?

No, the Form 4 reflects a compensation-related grant of deferred stock units, not an open-market purchase or sale. The award provides a right to future cash or shares, with no immediate trading in Elanco common stock reported in this transaction.

What plan governs the Elanco (ELAN) deferred stock unit grant?

The grant is governed by Elanco’s Executive Deferral and Stock Match Plan. Under this plan, the officer’s deferred stock units accumulate and are later settled in cash or Company common shares based on elections and the timing rules specified in the plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Correia de Simas Jose Manuel

(Last) (First) (Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS IN 46221

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SEE REMARKS

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Stock Units	(1)	03/06/2026		A		17,637.8425		(2)	(2)	Common Stock	17,637.8425	$23.36	22,280.4709	D

Explanation of Responses:

1. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.

2. Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

Remarks:

Executive Vice President, US Farm Animal Business

	/s/ Amy C. Seidel, as Attorney-in-Fact for Jose Manuel Correia de Simas	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.